24小时热门版块排行榜

>论坛更新日志 (3444)
>虫友互识 (966)
>文献求助 (260)
>导师招生 (171)
>休闲灌水 (163)
>考博 (135)
>教师之家 (88)
>硕博家园 (83)
>博后之家 (82)
>找工作 (77)
>论文投稿 (76)
>论文道贺祈福 (67)
>基金申请 (67)
>考研 (57)
>公派出国 (51)
>招聘信息布告栏 (38)

返回列表

zlwcw

木虫 (著名写手)

应助: 1 (幼儿园)
金币: 2021.1
散金: 225
红花: 8
帖子: 1274
在线: 219.7小时
虫号: 530429
注册: 2008-03-21
性别: GG
专业: 代谢性疾病药物药理

[交流] 【讨论】TERMINATION OF ACQUISITION AGREEMENT WITH WUXI PHARMATECH

CHARLES RIVER ANNOUNCES MUTUAL TERMINATION OF ACQUISITION AGREEMENT WITH WUXI PHARMATECH

– Board of Directors Approves $500 Million
Stock Repurchase Plan –

– Special Stockholder Meeting Canceled –

– Second-Quarter Earnings Release and Conference Call Rescheduled –

WILMINGTON, MA, July 29, 2010 – Charles River Laboratories International, Inc. (NYSE: CRL), a leading global provider of research models and associated services and of preclinical drug development services, today announced that it has mutually agreed with WuXi PharmaTech (Cayman) Inc. (NYSE: WX) to terminate their previously announced acquisition agreement. The Company also announced that its Board of Directors has authorized a new $500 million stock repurchase program.

The termination agreement provides for Charles River to pay WuXi a $30 million breakup fee for full satisfaction of the parties’ obligations under the acquisition agreement and includes mutual releases of any claims and liabilities arising out of or relating to the acquisition agreement. As a result of the termination of the acquisition agreement, the special meeting of Charles River stockholders to be held on August 5, 2010 has been canceled.

James C. Foster, Chairman, President and Chief Executive Officer said, “We believed that this transaction, which would have created the premier early-stage contract research organization, would have resulted in long-term strategic benefits for our business and our shareholders. We also value our stockholders’ views and given their concerns about the proposed transaction, and our commitment not to proceed without their support, we have decided that terminating the transaction is the appropriate action to take.

“Although we are disappointed in the outcome of the proposed transaction, our overall strategy remains unchanged. We intend to be the premier early-stage CRO and will continue to build our early development capabilities – specifically our discovery services – in order to support our clients’ efforts across a broader portion of the drug development pipeline. We will enhance our portfolio of essential products and services, deepen our scientific expertise and maintain our standards of exceptional client service, all of which distinguish Charles River as an industry leader and make us the strategic partner of choice in early-stage drug development.”

“The Board’s action to authorize a new stock repurchase plan at this time reflects both its belief that our stock price is substantially undervalued and also its faith in Charles River’s future prospects. Repurchasing our stock is another means of enhancing earnings growth and improving stockholder value,” he concluded.

Board Authorizes Stock Repurchase Plan

Charles River’s Board of Directors has authorized the repurchase of up to $500 million of its common stock. The Company is currently exploring alternatives for timely execution. The stock purchases may be made from time to time through a variety of methods, including open market repurchases such as block trades, 10b5-1 plans or otherwise in compliance with Rule 10b-18 of the federal securities laws and/or privately negotiated transactions. Funds for the repurchases are expected to come from cash on hand, cash generated by operations, our existing credit facilities or other financing.

Charles River has previously repurchased approximately 11 million shares under its prior $600 million stock repurchase authorization, and as of July 15, 2010, had approximately 66.3 million shares of common stock outstanding. That authorization, under which there was a remaining balance of approximately $145 million, has been canceled.

Repurchases may be commenced or suspended at any time or from time to time without prior notice, depending on our view of market conditions and other factors. There are currently no specific plans for the shares that may be purchased under the program.

回复此楼